This innovative drug has an annual peak sales potential of over EUR 2 billion.Progress has also been made in the indication cancer: Alongside the drug product Nexavar???, approved for the treatment of kidney and liver cancer and currently being investigated in more than 200 clinical studies with regard to its use in treating other forms of cancer, Bayer has also expanded its research activities in